cephalosporin c has been researched along with evernimicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beauchamp, D; Bergeron, MG; Bergeron, Y; Simard, M; Wang, E | 1 |
| Cacciapuoti, A; Nowakowski, J; Pavia, CS; Wormser, GP | 1 |
2 other study(ies) available for cephalosporin c and evernimicin
| Article | Year |
|---|---|
In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Ceftriaxone; Cephalosporins; Female; Leukopenia; Lung; Mice; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Pneumococcal; Serum Bactericidal Test; Streptococcus pneumoniae; Survival Analysis; Vancomycin | 2000 |
Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Borrelia burgdorferi Group; Ceftriaxone; Cephalosporins; Disease Models, Animal; Female; Lyme Disease; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Treatment Outcome | 2001 |